Polynucleotides or Tear-Trough Filler for Under-Eye Concerns: Which Is More Suitable?
Tear-trough filler and polynucleotide injections are not interchangeable. Hyaluronic-acid filler is mainly considered when a genuine hollow creates a shadow and structural volume is the main problem. Polynucleotides are intended for gradual, subtle changes in skin quality, such as fine crepiness or texture, rather than replacing significant volume. Neither treatment reliably removes every dark circle, eye bag or pigment change.
MK Aesthetics offers both tear-trough assessment and filler and polynucleotide treatment. Suitability depends on the causeânot which injectable is newest online.
Why do under-eye concerns need a diagnosis rather than a product choice?
âDark circlesâ and âtired eyesâ are descriptions, not single diagnoses. The appearance may come from one or several factors:
a groove between the lower eyelid and cheek casting a shadow
naturally thin skin showing vessels or underlying muscle
brown or grey pigmentation
loose or crepey skin
prominent lower-eyelid fat pads
fluid retention, malar oedema or festoons
irritation, allergy or repeated rubbing
loss of support in the upper cheek
Lighting and cameras can exaggerate shadows and cannot reliably show skin thickness or swelling. An in-person assessment should examine the lower eyelid, cheek and surrounding skin.
What does tear-trough filler aim to do?
Tear-trough filler usually contains cross-linked hyaluronic acid. It is placed beneath the skin to reduce the depth of a hollow and soften the shadow it creates. It may suit a carefully selected person with a clear structural groove, good skin quality and little tendency to puffiness.
It does not remove pigment, visible vessels or eye bags. Adding a water-attracting gel to someone with existing swelling can make the area look heavier. Very thin skin may reveal irregularities or blue-grey discolouration, and previous filler may remain present longer than expected. Sometimes cheek support should be assessed before the trough itself; sometimes filler is not appropriate at all.
The aim is improvement, not complete removal or perfect symmetry. Read the clinicâs guide to tear-trough filler suitability and risks.
What do polynucleotide injections aim to do?
Polynucleotides are purified chains of nucleotides, commonly derived from fish DNA. They are injected in small amounts and promoted as skin-quality treatments rather than structural fillers. The intended change is gradual: skin may appear better hydrated, smoother or slightly more resilient, but polynucleotides do not recreate the support provided by a volumising filler.
Evidence for the under-eye area is encouraging but still preliminary. A 2026 systematic review found six eligible studies involving 350 people. Five were split-face randomised trials, but all studies involved Korean or Thai cohorts, follow-up did not exceed six months, and methods varied. The authors concluded that polynucleotides may be reasonable for mild-to-moderate textural change but should be considered an adjunctânot a substitute for filler where significant structural volume is missing.
An earlier randomised split-face trial involved 27 participants and compared polynucleotides with non-cross-linked hyaluronic acid. Some measures of elasticity, hydration, roughness and pore volume improved, but the study was small and does not prove that every product or patient will respond similarly.
Which treatment matches which concern?
If the dominant issue is a true hollow with a shadow, filler may be discussed. If the main issue is fine crepiness or texture without significant volume loss, polynucleotides may be the more logical conversation. Neither is a reliable treatment for strong brown pigmentation, prominent vessels, substantial eye bags or marked fluid retention.
Several causes can coexist. Combining treatments is not automatically better: it adds cost, injections and cumulative risk. A staged plan allows each response to be judged first. No treatment, skincare, camouflage, medical investigation or surgical assessment may be more appropriate.
How do the results and treatment courses differ?
Filler creates an immediate volume change, although early swelling means the final result should not be judged on the day. The area may take one to two weeks to settle, and longevity varies with anatomy, product, placement and individual metabolism.
Polynucleotide changes are expected gradually over a course. Protocols differ and long-term durability remains uncertain. Temporary bumps are not the intended result. Consistent photographs and a planned review help judge subtle change.
Neither option should be sold as permanent, guaranteed or ârisk-freeâ. Ask why the proposed number of sessions or amount of product is appropriate for you.
What downtime should you expect?
Both treatments can cause redness, tenderness, swelling and bruising. Polynucleotides are usually placed through multiple small injections, so visible bumps may appear initially. Tear-trough filler may produce uneven swelling while it settles, and bruising can last longer than expected.
Allow social downtime before photographs, travel or important events. Follow written aftercare, avoid rubbing or massaging unless instructed, and ask when to resume exercise, make-up, active skincare and contact lenses.
What are the important risks and warning signs?
Polynucleotide risks include discomfort, bruising, prolonged swelling, infection, nodules, inflammatory reactions, allergy and an unsatisfactory result. Ask about the source of the product, particularly if you have a fish allergy, and disclose previous injectable reactions, medicines, pregnancy or breastfeeding.
Tear-trough filler can also cause contour irregularities, persistent oedema, blue-grey discolouration, delayed inflammation or migration. A 2025 review of periorbital filler complications describes both early and delayed problems. Rare vascular complications can threaten skin or vision.
Contact the treating clinic urgently for severe or increasing pain, blanching, mottled or dusky skin, rapidly worsening swelling, heat, discharge or feeling unwell. Blurred or lost vision, double vision, severe eye pain or a new neurological symptom after any facial injection requires immediate emergency assessment.
What should you ask at a Milton Keynes consultation?
The NHS recommends asking about practitioner qualifications, product source, experience, complications, aftercare and what happens if something goes wrong. Useful under-eye questions include:
Is my concern mainly hollowing, pigment, vessels, texture, laxity or swelling?
What will the proposed treatment not change?
Is previous filler still present or contributing to puffiness?
What product will be used, and what evidence supports it for this area?
What downtime and course should I realistically expect?
What is the urgent complication plan, including outside normal hours?
Would no treatment or another assessment be safer?
You should have time to think. Responsible cosmetic marketing should not trivialise injections, exploit insecurity or pressure you into a course.
Frequently asked questions
Are polynucleotides a type of filler?
They are injected products but are not intended to sculpt or replace volume like cross-linked hyaluronic-acid dermal filler. Temporary swelling is not the final effect.
Can either treatment remove dark circles completely?
No. Filler may soften a hollowâs shadow, while polynucleotides may be considered for subtle skin-quality concerns. Neither reliably removes pigment, vessels, eye bags or every mixed cause.
Is tear-trough filler reversible?
Hyaluronic-acid filler can sometimes be dissolved with hyaluronidase, but this is a medical treatment with limitations and risks. âReversibleâ does not mean risk-free or guarantee an exact return to baseline.
Where can I discuss the options in Milton Keynes?
MK Aesthetics is based in Shenley Brook End. You can read the clinicâs polynucleotide evidence and downtime guide and use the contact page to enquire about an assessment. A consultation may lead to one option, another recommendation or advice not to proceed.



Comments